Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis (DIFFUPERPED)

This is a pilote monocentric prospective study about pediatric peritonitis and antibiotics pharmacokinetic and pharmacodynamic. The investigators will include 41 patients between 3 and 17 years-old during 2 years in the University Hospital of Nancy.

The aim of this study is to determine if the beta-lactam dosages in children recommended by the guidelines for management of intra-abdominal infections permitted the achievement of adequatly serum and peritoneal concentrations in the medical and surgical management of peritonitis.

The investigators will collected serum and peritoneal fluid samples at 3 different times: peritoneal incision, end of surgery, 2 days and 5 days after surgery in order to compare the concentrations and the minimal inhibitor concentration of bacteria.

The hypothesis is that of a serum and peritoneal antibiotic under dosage.

Study Overview

• Status: Not yet recruiting
• Conditions: Appendicitis; Peritonitis; Children, Only; Antibiotic Toxicity
• Intervention / Treatment: Other: Dosage of serum and peritoneal of the betalactam used for antibiotic treatment

Detailed Description

Pediatric population with localized or generalized appendicular peritonitis with surgical management at the Nancy University Hospital.

Patients are usually taken in emergency at the Pediatric Emergency Department (Children's Hospital, CHRU Nancy). The diagnosis of peritonitis is then made or confirmed by clinical examination and paraclinical tests (biology and imaging).

Written informed consent is obtained from one of the parental authority holders, allowing inclusion in the study. An information document adapted to the child's understanding will also be sent to him/her. The child's non-opposition will be sought if he/she is old enough to understand. The information will be given jointly to the child and to the legal guardians present at the patient's bed at the time of diagnosis of peritonitis. The reflection period will correspond to the interval between this information and the management in the operating room. This may vary depending on the occupation of the operating room.

The diagnosis of appendicular peritonitis is made by the surgeon (routine care). The child is included.

Antibiotic therapy is started IV according to the protocol in force at the CHRU (routine care):

- Cefotaxime (200 mg/kg/d, 4 IV administrations) + Metronidazole (20-30 mg/kg/d, 3 IV administrations)+/-Gentamicin (3-8 mg/kg/d IV)

Specific biological samples and collections are taken for the research:

• A blood sample (1mL) (S0) after injection of the antibiotic and before appendicular section, non-invasive because performed on peripheral venous route.
• A blood sample (1mL) (S1) at the end of the operation, either when the peripheral venous route is placed if possible (non-invasive), otherwise at the periphery (invasive).
• If a drainage of the peritoneal cavity is in place, a non-invasive collection of peritoneal fluid (5 mL) on the drain will be performed (P1) at D2.
• If generalized peritonitis, an additional blood collection (1mL) at D5 (S2) during the biological check-up (routine care). If an abdominal drainage is still in place, a non-invasive collection of peritoneal fluid (5mL) on drain will be performed (P2). At D5, the patients are under appropriate antibiotic therapy.

Specifically for research, betalactam assays are performed on S0, S1, S2, P0, P1 and P2 once all samples have been sent to Pharmacology.

Bacteriological analyses are performed on P0 (routine care), P1 and P2 in real time.

The following specific data will be collected: time of first antibiotic administration, time of sampling (S0, S1 and P0), time of surgery start. Data concerning antibiotic therapy (dosage, frequency of administration) will be collected during the entire hospitalization period as well as the time of the other samples if applicable (S2, P1 and P2).

Clinical and biological data are collected, including the visit at 4-6 weeks after discharge. (In routine care, a visit at 1 month post-op is performed). The investigator looks for AEs or SAEs. At the end of this post-operative visit, the patient is discharged from the study.

The volume of blood collected in the framework of the research is estimated at 3mL, i.e. less than 2.5% of the total blood volume over the inclusion period. The maximum total volume collected is 24 mL (6 mL for research, 18 mL for care, i.e. 3 samples of CBC, blood ionogram and CRP).

Blood and peritoneal samples :

The 3 blood samples as well as the 2 (possibly 3) peritoneal samples will be taken by a nurse and will be placed in a specific bag. Each sampling time will be clearly identified on the sample and a traceability form will be completed and sent to the Pharmacology and Toxicology laboratory.

• Study Type: Interventional
• Enrollment (Anticipated): 41
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 17 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• diagnosis of intra-abdominal infection : localized or generalized peritonitis secondary to appendix

Exclusion Criteria:

• betalactams allergy
• peritonitis with other etiology than appendix
• antibiotic treatment longer than 24h

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: Pediatric Peritonitis; Patient (from 3 to 17 years-old) treated for appendicular peritonitis. It includes surgical treatment (appendicectomy, peritoneal toilet) and antibiotherapy according to French recommendation.

Other: Dosage of serum and peritoneal of the betalactam used for antibiotic treatment; All patients will have antibiotherapy according to French recommendation. Antibiotics recommended are: cefotaxime 200mg/kg/d / OR amoxicillin/clavulanic acid 25 mg/kg x 3 /d OR piperacilline/tazobactam 100 mg/kg/d Blood samples will be collected before surgery and after surgery (for all patients). Peritoneal sample will be collected during surgery (for all patients). Additionnal optionnal blood sample could be collected on Day 5 after surgery. Additionnal optionnal peritoneal samples could be collected on Day 2 and Day 5. Dosage of serum and peritoneal of the used betalactam will be performed by High Performance Liquid Chromatography Method

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
antibiotic concentration	Serum betalactams concentrations at different times	Peritoneal incision, end of surgery, Day+5 after surgery if systemic peritonitis,
antibiotic concentration	Peritonal betalactams concentrations at different times	During surgery, Day+2 after surgery if drain peritonal, Day+5 after surgery if systemic peritonitis,

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determine elimination rate constant Kel	It is the first order rate constant describing drug elimination from the body.	Statistical analysis after 2 years of inclusion
Determine estimated initial concentrationf C0	Initial concentration of antibiotic in the body	Statistical analysis after 2 years of inclusion
Determine Area Under the Curve AUC.	It is the definite integral of a curve that describes the variation of a drug concentration in blood plasma as a function of time.	Statistical analysis after 2 years of inclusion
Determine Half-life	It is a pharmacokinetic parameter that is defined as the time it takes for the concentration of the drug in the plasma or the total amount in the body to be reduced by 50%.	Statistical analysis after 2 years of inclusion
Determine distribution volume	It is a pharmacokinetic parameter representing an individual drug's propensity to either remain in the plasma or redistribute to other tissue compartments.	Statistical analysis after 2 years of inclusion
Determine Clearance or betalactams in children	It is a pharmacokinetic measurement of the volume of plasma from which a substance is completely removed per unit time.	Statistical analysis after 2 years of inclusion
Evaluate the relationship between serum and peritoneal concentrations of beta-lactam	Determination of the antibiotic diffusion coefficient through the peritoneal membrane : difference between serum concentration and peritoneal concentration of betalactam	Statistical analysis after 2 years of inclusion
Proportion of different bacteria	Describe the local bacterial ecology	Statistical analysis after 2 years of inclusion
Proportion of sensitive and resistant germs to betalactam antibiotics	Describe the local bacterial ecology	Statistical analysis after 2 years of inclusion
Description of minimal inhibition concentration for bacterias	Describe the local bacterial ecology	Statistical analysis after 2 years of inclusion
Factors associated with an antibiotic under-dosage	Factors statistically associated with antibiotic under dosage defined by serum and peritonal concentrations < 4*MIC using multivariate analysis.	Statistical analysis after 2 years of inclusion
Factors associated with an antibiotic overdose	Factors statistically associated with antibiotic overdose defined by serum and peritonal concentrations >10*MIC using multivariate analysis.	Statistical analysis after 2 years of inclusion
Evaluation of duration of hospitalization	Describe the clinical efficacy of antibiotic protocol	Statistical analysis after 2 years of inclusion
Mean delay for apyrexia	Describe the clinical efficacy of antibiotic protocol	Statistical analysis after 2 years of inclusion
Clinical complications	Describe the clinical efficacy of antibiotic protocol	Statistical analysis after 2 years of inclusion

Collaborators and Investigators

• Sponsor: Central Hospital, Nancy, France
• Collaborators: PAPE Elise

Study record dates

Study Major Dates

• Study Start (Anticipated): March 31, 2022
• Primary Completion (Anticipated): March 31, 2024
• Study Completion (Anticipated): June 30, 2024

Study Registration Dates

• First Submitted: January 20, 2022
• First Submitted That Met QC Criteria: March 24, 2022
• First Posted (Actual): April 4, 2022

Study Record Updates

• Last Update Posted (Actual): April 4, 2022
• Last Update Submitted That Met QC Criteria: March 24, 2022
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: Children Peritonitis; Antibiotic diffusion; Pharmacocinetic study
• Additional Relevant MeSH Terms: Digestive System Diseases; Infections; Peritoneal Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Cecal Diseases; Intraabdominal Infections; Appendicitis; Peritonitis; Anti-Infective Agents; Anti-Bacterial Agents; beta-Lactams
• Other Study ID Numbers: 2021-A00378-33

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No